Our therapeutic experience in managing complex hospital-based studies spans multiple therapeutic areas and specific indications across Phase I-III studies. Our combined experience in clinical pharmacology and clinical development includes Respiratory, Anti-Infectives & Vaccines, Dermatology, Gastro-Intestinal, Critical Care Medicine, Medical Devices, Hepatic and Billary, and Pulmonary. It is this wide therapeutic experience working in various indications which enables us to bring insight to your clinical development and manage the most challenging studies.
COVID-19 Clinical Trials
Our expertise in managing over 120 hospital-based critical care, infectious diseases and respiratory studies provides the experience you can lean on to conduct clinical trials for COVID-19. We have over four decades of expertise from First-In-Human studies through to Phase IV delivered by tight-knit teams, motivated and forward-thinking. We will prioritise any COVID-19 RFP for input and review allowing important research to move rapidly at this important time. We have a streamlined contracting process in place and can start work on projects with a Letter of Intent – given the circumstances our agility enables us to remove hurdles and progress clinical research that will improve all our lives.
How our scientific affairs group adds value – and reduces risk
Dr Simon Hutchings, Director of Scientific Affairs
Discover how the experience and expertise of our team enables us to reduce risk – including regulatory risk – and focus on designing studies to gain maximum valuable data.
If you think we could be right for you, get in touch.